Briacell Therapeutics Corp. 已正式启动其在加拿大的首个临床研究中心——位于多伦多的Sunnybrook健康科学中心，以推进其针对转移性乳腺癌的关键性III期临床试验。这一进展标志着该公司核心候选疗法Bria-IMT™联合检查点抑制剂的研究进入了一个重要阶段，旨在评估其在难治性转移性乳腺癌患者中的安全性与有效性。Sunnybrook作为加拿大顶尖的癌症研究与治疗机构之一，其参与有望加速患者招募并增强试验数据的权威性。此次III期试验的成功与否，对Briacell的未来商业化前景及股价走势可能产生深远影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.